Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 5.6% on Monday . The stock traded as low as C$0.17 and last traded at C$0.17. Approximately 169,000 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 477,591 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$24.04 million, a PE ratio of -4.81 and a beta of 0.20. The stock has a 50 day moving average price of C$0.21 and a two-hundred day moving average price of C$0.13.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Learn Technical Analysis Skills to Master the Stock Market
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Breakout Stocks: What They Are and How to Identify Them
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Top Stocks Investing in 5G Technology
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
